Navigation Links
Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
Date:2/19/2009

t Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may also differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environments, including the possible need to raise additional capital and the possibility that Cadence's share price may decline after the transaction is closed. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
      
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 AutoTex ... sporting the iconic pink ribbon in support of breast ... popular month for businesses and non-profits to “go pink” ... cause. , AutoTex PINK is a woman-owned company that ... They are committed to partnering with their customers ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... Julie Kuriakose, MD; Physician, ... will discuss how restaurants can become more allergy-friendly and ... restrictions at the 2014 Allergy Eats Food Allergy ... 21 in New York City. , “I’m extremely delighted ... such an engaged industry audience. As food allergies become ...
(Date:9/30/2014)... Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ... tolerate their prescribed medical device known as CPAP (continuous ... which supports the airway during sleep. , In today’s ... and increasingly difficult to get. Snoring and sleep apnea ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2
... when choosing mates, study finds , MONDAY, June 29 (HealthDay ... a mate, according to a U.S. study that challenges the ... recruited 350 undergraduates for speed-dating events. In half the events, ... in one location. The roles were reversed in the other ...
... ... their perspectives on eye care and safety. , ... Minneapolis, MN (PRWEB) June 29, 2009 -- Stop squinting…proper eye care and ... displays in all their brilliance and clarity., , , The Healthcare Scoop , in recognition ...
... , Two MuGard US Patents Issued , , DALLAS, ... (OTC Bulletin Board: ACCP), announced today that its European partner, ... MuGard in Greece. This follows previous ... license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
... identified and described a mechanism whereby a single-base change in ... The focus in this study was on a common ... only a slightly increased risk of cancer. However, the risk ... and by almost 100% of African populations. The high ...
... particular can gene raise a man,s risk of familial, or ... disease, according to new research by scientists at the National ... to be identified that affects the risk of familial testicular ... The study appears in the July 2009 Cancer ...
Cached Medicine News:Health News:Maybe Men Aren't So Picky After All 2Health News:The Healthcare Scoop Community Says 'Eye Care' 2Health News:The Healthcare Scoop Community Says 'Eye Care' 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 2Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 3Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2Health News:Risk of cancer 2Health News:Second gene linked to familial testicular cancer 2Health News:Second gene linked to familial testicular cancer 3
(Date:9/29/2014)... , Sept. 29, 2014  Repeated exposure to broad-spectrum ... associated with early childhood obesity, say researchers from The ... a retrospective study based on data from electronic health ... The researchers found that children with four or ... particularly more likely to be at risk for obesity. ...
(Date:9/29/2014)... CHICAGO , Sept. 29, 2014 ... clinical trials are conducted according to good clinical ... the HOPA Investigational Drug Service Best Practice Standards, ... best practice standards and guidance for pharmacists and ... Drug Service Best Practice Standards emphasizes the critical ...
(Date:9/29/2014)... 29, 2014 EU5 Capsule Endoscopy Systems Market ... GlobalData,s new report, "EU5 Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments - Capsule ... The report also provides company shares and ...
Breaking Medicine Technology:Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3
... 2011 PAREXEL International Corporation (NASDAQ: PRXL ... and fiscal year ended June 30, 2011.   ... consolidated service revenue increased by 5.2% to $310.5 million ...  Excluding the positive impact from foreign exchange movements in ...
... is a law that requires healthcare organizations to convert medical ... at the forefront of many leading managed hosting providers. INetU ... and HITECH compliance, has been asked to address these concerns ... session on Wednesday, August 10. "The HITECH Act ...
Cached Medicine Technology:PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 2PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 3PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 4PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 5PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 6PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 7PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 8PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 9PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 10PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 11PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 12PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 13HITECH Act Puts Security of Electronic Medical Records in Hands of Hosting Providers 2
... design permits continuous irrigation through ... the Foley Catheter. 3-Way Catheters ... as well as LUBRICATH coatings, ... of models including Suggs, Emmett, ...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: